BioELife Corp. Logo

BioELife Corp.

LITH

(1.8)
Stock Price

0,00 USD

-240.67% ROA

0% ROE

-0x PER

Market Cap.

9,00 USD

-85.98% DER

0% Yield

0% NPM

BioELife Corp. Stock Analysis

BioELife Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioELife Corp. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (170.28%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-86%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROA

The stock's ROA (-240.67%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

BioELife Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioELife Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BioELife Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioELife Corp. Revenue
Year Revenue Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioELife Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioELife Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 8.931
2008 14.297 37.53%
2009 9.722 -47.06%
2010 23.000 57.73%
2011 73.404 68.67%
2012 70.271 -4.46%
2013 67.472 -4.15%
2014 463.619 85.45%
2015 61.352 -655.67%
2016 103.964 40.99%
2017 80.816 -28.64%
2018 73.743 -9.59%
2019 78.588 6.17%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioELife Corp. EBITDA
Year EBITDA Growth
2007 -67.497
2008 -47.152 -43.15%
2009 -50.582 6.78%
2010 -58.912 14.14%
2011 -74.980 21.43%
2012 -70.271 -6.7%
2013 -67.472 -4.15%
2014 -463.619 85.45%
2015 -61.352 -655.67%
2016 -103.964 40.99%
2017 -125.059 16.87%
2018 -73.743 -69.59%
2019 -78.588 6.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioELife Corp. Gross Profit
Year Gross Profit Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -4.608 100%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioELife Corp. Net Profit
Year Net Profit Growth
2007 -54.673
2008 -51.696 -5.76%
2009 -52.399 1.34%
2010 -65.868 20.45%
2011 -85.508 22.97%
2012 -84.839 -0.79%
2013 -67.004 -26.62%
2014 -498.326 86.55%
2015 -82.187 -506.33%
2016 -209.513 60.77%
2017 -246.858 15.13%
2018 -336.958 26.74%
2019 -193.640 -74.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioELife Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioELife Corp. Free Cashflow
Year Free Cashflow Growth
2007 -45.387
2008 -58.078 21.85%
2009 -41.938 -38.49%
2010 -48.346 13.25%
2011 -65.480 26.17%
2012 -46.568 -40.61%
2013 -59.276 21.44%
2014 -36.783 -61.15%
2015 -33.367 -10.24%
2016 -133.849 75.07%
2017 -122.050 -9.67%
2018 -76.691 -59.15%
2019 -39.291 -95.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioELife Corp. Operating Cashflow
Year Operating Cashflow Growth
2007 -40.387
2008 -58.078 30.46%
2009 -30.913 -87.88%
2010 -45.346 31.83%
2011 -65.480 30.75%
2012 -46.568 -40.61%
2013 -59.276 21.44%
2014 -36.783 -61.15%
2015 -33.367 -10.24%
2016 -129.404 74.21%
2017 -122.050 -6.03%
2018 -76.071 -60.44%
2019 -35.793 -112.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioELife Corp. Capital Expenditure
Year Capital Expenditure Growth
2007 5.000
2008 0 0%
2009 11.025 100%
2010 3.000 -267.5%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 4.445 100%
2017 0 0%
2018 620 100%
2019 3.498 82.28%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioELife Corp. Equity
Year Equity Growth
2007 31.249
2008 -20.447 252.83%
2009 -71.035 71.22%
2010 -134.444 47.16%
2011 -166.194 19.1%
2012 -247.156 32.76%
2013 -304.646 18.87%
2014 -368.274 17.28%
2015 -217.806 -69.08%
2016 -290.301 24.97%
2017 -70.612 -311.12%
2018 -325.160 78.28%
2019 6.927 4794.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioELife Corp. Assets
Year Assets Growth
2007 38.128
2008 581 -6462.48%
2009 3.499 83.4%
2010 0 0%
2011 1.398 100%
2012 0 0%
2013 4.524 100%
2014 256 -1667.19%
2015 1.389 81.57%
2016 31.422 95.58%
2017 376.535 91.65%
2018 140.006 -168.94%
2019 47.881 -192.4%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioELife Corp. Liabilities
Year Liabilities Growth
2007 6.879
2008 21.028 67.29%
2009 74.534 71.79%
2010 134.444 44.56%
2011 167.592 19.78%
2012 247.156 32.19%
2013 309.170 20.06%
2014 368.530 16.11%
2015 219.195 -68.13%
2016 321.723 31.87%
2017 447.147 28.05%
2018 465.166 3.87%
2019 40.954 -1035.83%

BioELife Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.13
Price to Earning Ratio
-0x
Price To Sales Ratio
0x
POCF Ratio
-0
PFCF Ratio
-0
Price to Book Ratio
-0
EV to Sales
0
EV Over EBITDA
-3.74
EV to Operating CashFlow
-3.62
EV to FreeCashFlow
-3.59
Earnings Yield
-129316.82
FreeCashFlow Yield
-8521.22
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.6
Graham NetNet
-0.13

Income Statement Metrics

Net Income per Share
-0.13
Income Quality
0.23
ROE
1.7
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
0.01
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
1.62
Return on Tangible Assets
-2.41
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,05
Book Value per Share
-0,12
Tangible Book Value per Share
-0.12
Shareholders Equity per Share
-0.12
Interest Debt per Share
0.14
Debt to Equity
-0.86
Debt to Assets
2
Net Debt to EBITDA
-3.74
Current Ratio
0.27
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.86
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
31062.56

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioELife Corp. Dividends
Year Dividends Growth

BioELife Corp. Profile

About BioELife Corp.

BioELife Corp. operates in cannabinoid market. It offers cannabinoid products, such as combo adult gummies with chirorub, combo tincture with chirorub, intensive relief rub, tinctures, adult gummies, premium pre-rolls, and flowers. The company was formerly known as US Lithium Corp. and changed its name to BioELife Corp. in March 2020. The company was founded in 2006 and is based in Seal Beach, California.

CEO
Mr. Gregory C. Rotelli
Employee
0
Address
12340 Seal Beach Boulevard
Seal Beach, 90740

BioELife Corp. Executives & BODs

BioELife Corp. Executives & BODs
# Name Age
1 Mr. Gregory C. Rotelli
Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer & Chairman
70
2 Daniel C. Masters
Legal Counsel
70

BioELife Corp. Competitors

MC Endeavors, Inc. Logo
MC Endeavors, Inc.

MSMY

(1.2)
Kali, Inc. Logo
Kali, Inc.

KALY

(0.0)
HempAmericana, Inc Logo
HempAmericana, Inc

HMPQ

(0.0)
Eisai Co., Ltd. Logo
Eisai Co., Ltd.

ESAIY

()
SOHM, Inc. Logo
SOHM, Inc.

SHMN

(0.0)
The Flowr Corporation Logo
The Flowr Corporation

FLWPF

(0.8)
BellRock Brands Inc. Logo
BellRock Brands Inc.

DXBRF

(0.0)
Pharmadrug Inc. Logo
Pharmadrug Inc.

LMLLF

(1.2)
1933 Industries Inc. Logo
1933 Industries Inc.

TGIFF

(0.8)